The Frequency of Occurrence of Anti-cardiac Receptor Autoantibodies and their Correlation with Clinical Manifestation in Patients with Hypertrophic Cardiomyopathy

References

• Maron B. J., Epstein S. E. Hypertrophic cardiomyopathy: A discussion of nomenclature. Am. J. Cardiol. 1979; 43: 1242–1244
   PubMed Web of Science ®Google Scholar
• Jarcho J. A, McKenna W. J, Pare J. A.P., et al. Mapping of a gene for familial hypertrophic cardiomyopathy to chromosome 14ql. N. Engl. J. Med. 1989; 321: 1372–1378
   PubMed Web of Science ®Google Scholar
• Watkins H., MacRae C., Thierfelder L., et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome Iq3. Nat. Genet 1993; 3: 333–337
   PubMed Web of Science ®Google Scholar
• Thierfelder L., MacKae C., Watkins H., et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc. Nat. Acad. Sci. USA 1993; 90: 6270–6274
   PubMed Web of Science ®Google Scholar
• Carrier L., Hengstenberg C., Beckmann J. S., et al. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat. Genet. 1993; 4: 311–313
   PubMed Web of Science ®Google Scholar
• Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosincardiac troponin T-mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77: 701–712
   PubMed Web of Science ®Google Scholar
• Poetter K., Jiang H., Hassanzadeh S., et al. Mutations in either the essential or regulatory light chains of myosin are associated with myopathy in human heartskeletal muscle. Nat. Genet. 1996; 13: 63–68
   PubMed Web of Science ®Google Scholar
• Hengstenberg C., Schwartz K. Molecular Genetics of familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 1994; 26: 3–10
   PubMed Web of Science ®Google Scholar
• Watkins H., Conner D., Thierfelder L., et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 1995; 11: 434–437
   PubMed Web of Science ®Google Scholar
• Kimura A., Harada H., Park J. E., et al. Mutation in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 1997; 16: 379–382
   PubMed Web of Science ®Google Scholar
• Boudonas G., Boura P., Lefkos N., Zacharioydaki E., Efthymiadis A. A possible role for AAB in left ventricular hypertrophy. Cardiology 1994; 84: 278–283
   PubMed Web of Science ®Google Scholar
• Autore C., Fiorito S., Pelliccia A., et al. Antimitochondrial autoantibodies in myocardial hypertrophy: comparison between hypertrophic cardiomyopathy, hypertensive heart disease, athlete's heart. Am. Heart. J. 1988; 116: 496–500
   PubMed Web of Science ®Google Scholar
• Fu M. L.X., Hoebeke J., Matsui S., et al. Autoantibodies against cardiac G-protein-coupled receptors define different populations with cardiomyopathies but not with hypertension. Clin. Immunol. Immunopath. 1994; 72: 15–20
   PubMedGoogle Scholar
• Matsui S., Fu M. L.X., Shimizu M., et al. Dilated cardiomyopathy defines serum autoantibodies against G-protein-coupled cardiovascular receptors. Autoimmunity 1995; 21: 85–88
   PubMed Web of Science ®Google Scholar
• Caforio A. L.P., Grazzini M., Mann J. M., et al. Identification of alpha-and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilative cardiomyopathy. Circulation 1992; 85: 1734–1742
   PubMed Web of Science ®Google Scholar
• Latif N., Baker C. S, Dunn M. J, Brady P., Yacoub M. H. Frequencyspecificity of antiheart antibodies in patients with dilative cardiomyopathy detected using SDS-PAGEWestern blotting. J. Am. Coll. Cardiol. 1993; 22: 1378–1384
   PubMed Web of Science ®Google Scholar
• Dörffel W. V, Felix S. F, Wallukat G., et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997; 95: 1994–1997
   PubMed Web of Science ®Google Scholar
• Furuta H., Guo D. F., Inagami T. Molecular cloningsequencing of the gene encoding human angiotensin II type 1 receptor. Biochem. Biophys. Res. Comm. 1992; 183: 8–13
   PubMed Web of Science ®Google Scholar
• Bruno J. F, Whittaker J., Song J., et al. Molecular cloningsequencing of a cDNA encoding a human alpha la adrenergic receptor. Biochem. Biophys. Res. Comm. 1991; 179: 1485–1490
   PubMed Web of Science ®Google Scholar
• Frielle T., Collins S., Daniel K. W., et al. Cloning of the cDNA for the human β1-adrenergic receptor. Proc. Nat. Acad. Sci. 1987; 84: 7920–7924
   PubMed Web of Science ®Google Scholar
• Peralta E. G, Winslow J. W, Peterson G. L., et al. Primary structurebiochemical properties of a M2-receptor. Science 1987; 230: 600–605
   Google Scholar
• Fu M. L.X., Magnuson Y., Bergh C., et al. Localization of functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilative cardiomyopathy. J. Clin. Invest. 1993; 91: 1964–1968
   PubMed Web of Science ®Google Scholar
• Voss A., Kurths J., Kleiner H. J, Witt A., Wessel N. Improved analysis of heart rate variability by methods of non-linear dynamics. J. Electrocardiol. 1995; 28(suppl)81–88
   PubMed Web of Science ®Google Scholar
• Voss A., Kurths J., Kleiner H. J., et al. The application of methods of non-linear dynamics for the improvedpredictive recognition of patients threatened by sudden cardiac death. Cardiovas. Res. 1996; 31: 419–433
   PubMed Web of Science ®Google Scholar
• Herskowitz A., Neumann D. A., Ansari A. A. Concepts of autoimmunity applied to idiopathic dilated cardiomyoparty. J. Am. Coll. Cardiol. 1993; 22: 1385–1388
   PubMed Web of Science ®Google Scholar
• Fauci A. S. Activationregulation of human immune responses: implications in normaldisease states. Ann. Int. Med 1983; 99: 61–75
   PubMed Web of Science ®Google Scholar
• Fallen E. L, Kamath M. V., Ghista D. N. Power spectrum of heart rate variability: a non-invasive test of integrated neurocardiac function. Clin. Invest. Med. 1988; 213: 331–340
   Google Scholar
• Akselrod S., Gordon D., Ubel F. A, Shannon D. C, Barger A. C., , Cohen R. J, et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213: 220–222
   PubMed Web of Science ®Google Scholar
• Voss A., Esperer H. D. Herzfrequenzvariabilität. Definition, Analyse und klinische Bedeutung. Herz & Rhythmus 1994; 6: 1–7, part 1
   Google Scholar
• Herz & Rhythmus 1995; 7: 3–8, part 2
   Google Scholar
• Ahnve S., Gilpin E., Madsen E. B., et al. Prognostic importance of QTc-interval at discharge after acute myocardial infarction: a multicenter study of 865 patients. Am. Heart. J. 1984; 108: 395–400
   PubMed Web of Science ®Google Scholar
• Algra A., Tijssen J. G., Roelandt J. R., et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83: 1888–1894
   PubMed Web of Science ®Google Scholar
• Kleiger R. E, Stein P. K, Bosner M. S., Rottman J. N. Time domain measurements of heart rate variability. Cardiol. Clin. 1992; 10: 487–498
   PubMedGoogle Scholar
• Kleiger R. E, Miller J. P., Bigger J. T., et al. Decreased heart beat variabilityits association with increased mortality after acute myocardial infarction. Am. J. Cardiol. 1987; 59: 256–262
   PubMed Web of Science ®Google Scholar
• Maron B. J, Bonow R. O, Cannon R. O, Leon M. B., Epstein S. E. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, therapy (I. part). N. Engl. J. Med. 1987; 316: 780–789
   PubMed Web of Science ®Google Scholar
• Maron B. J, Wolfson J. K, Epstein S. E., Roberts W. C. Intermural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1986; 8: 545–550
   PubMed Web of Science ®Google Scholar